Last reviewed · How we verify
Intravitreal triamcinolone
Intravitreal triamcinolone is a Corticosteroid Small molecule drug developed by University of Sao Paulo. It is currently in Phase 3 development for Diabetic macular edema, Retinal vein occlusion-related macular edema, Uveitic macular edema. Also known as: Triancinolona (Ophthalmos).
Intravitreal triamcinolone is a corticosteroid injected directly into the eye that suppresses inflammation and reduces vascular permeability in retinal diseases.
Intravitreal triamcinolone is a corticosteroid injected directly into the eye that suppresses inflammation and reduces vascular permeability in retinal diseases. Used for Diabetic macular edema, Retinal vein occlusion-related macular edema, Uveitic macular edema.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Intravitreal triamcinolone |
|---|---|
| Also known as | Triancinolona (Ophthalmos) |
| Sponsor | University of Sao Paulo |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Triamcinolone acetonide is a synthetic glucocorticoid that binds to glucocorticoid receptors in ocular tissues, inhibiting inflammatory cytokine production and reducing edema. When administered intravitreally, it achieves high local concentrations in the posterior segment of the eye, making it effective for treating inflammatory and vascular retinal conditions without systemic exposure.
Approved indications
- Diabetic macular edema
- Retinal vein occlusion-related macular edema
- Uveitic macular edema
- Age-related macular degeneration (adjunctive)
Common side effects
- Elevated intraocular pressure
- Cataract progression
- Endophthalmitis
- Vitreous hemorrhage
- Floaters
Key clinical trials
- Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent (NA)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Triamcinolone vs. Laser for Diabetic Macular Edema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal triamcinolone CI brief — competitive landscape report
- Intravitreal triamcinolone updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI
Frequently asked questions about Intravitreal triamcinolone
What is Intravitreal triamcinolone?
How does Intravitreal triamcinolone work?
What is Intravitreal triamcinolone used for?
Who makes Intravitreal triamcinolone?
Is Intravitreal triamcinolone also known as anything else?
What drug class is Intravitreal triamcinolone in?
What development phase is Intravitreal triamcinolone in?
What are the side effects of Intravitreal triamcinolone?
What does Intravitreal triamcinolone target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: University of Sao Paulo — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Diabetic macular edema
- Indication: Drugs for Retinal vein occlusion-related macular edema
- Indication: Drugs for Uveitic macular edema
- Also known as: Triancinolona (Ophthalmos)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing